Oral Candidiasis Flashcards

1
Q

Pathophysiology of oral candidiasis

A
  • AKA thursh, oral candidosis, pseudomembranous candidiasis or moniliasis
  • mucocutaneous opportunisic infection caused by Candida species
  • Candida organisms = fungi that noramlly live in oral cavity (25-75% peole have it)
  • if normal flora compromised, Candida voergrowth and direct tissue invasion can occur
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is most common fungal infection found in immunocompetent and immunocompromised populations

A
  • oral candidiasis
  • prevalence is greatest among infants and elderly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what disease states are risk factors for developing oral canidiasis

A

Addison disease

Anemia (due to iron, folic acid or vitamin B12 deficiency)

Diabetes mellitus

HIV infection and AIDS

Hypothyroidism

Leukemia and head/neck cancer

Psoriasis

Sjogren syndrome

Xerostomia (dry mouth); may be caused by anticholinergic drugs, radiation therapy, dentures or dental appliances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what mediciations are risk factors for Oral candidiasis

A

Broad-spectrum antibiotics

Cytotoxic chemotherapy

Immunosuppressive drugs

Inhaled corticosteroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are risk factors associated with oral candidiasis tht are not diseae states or medications

A
  • infancy/childhood (underveloped immune system)
  • local mucosal trauma
  • organ and stem cell transplantation
  • parenteral nutrition
  • poor dental or denture hygiene
  • pregnancy
  • smoking tobacco

surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what candidia species causes more oral candidal ifnections

A

C. albicans (90% cases)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

relationship between HIV and oral candidial ifnection

A
  • HIV pandemic contributed greatly to resurgence of oral candidial infect
  • mitigated by effeective antiretroviral therapy
  • patients with low CD4 counts and/or AIDS can experience recurrent infections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are goals of oral candidal infection therapy

A
  • resolve infection or reduce acute candidal overgrowth to level that can be controlled by host defences -> prevent complication
  • prevent recurrences by managing underlying risk factors (use of inhaled corticosteroirds, poor dental hygiene, uncontrolled diabetes mellitus)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

how to asses patients with oral candidiasis

A
  • based on clinicla recognition of typical lesions, microbiologictests or suspected resistance to antifungal agent
  • can be localized (primary oral candidiasis): acute pseudomembraneous (thursh), erythematous or hyperplastic candidiasis
  • can also be menifestation of a generalized candidal infection (secondar oral candidiasis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

assessment of Acute pseudomembranous candidiasis

(thrush)

A
  • creamy whitish yellow elevated plaques -> tongue, soft palate and inner cheek
  • plaques easily wiped off exposing a raw, erthematous base that is not usually painful
  • commonly diagnoses in frist few weeks of infants life, in elderly patients and those with underling HIV infection
  • can persits for several months or years esp if taking inhaled or intraoral topical corticosteroids or HIV infected individuals
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

assessment of Erythematous candidiasis (atrophic candidiasis)

A
  • found on palate and tongue, can cause depapillation and dekeratinization
  • lesions vary in size and accompanied by inflammation of surrounding tissues
  • develop from pseudomembranous candidiasis as plaques are shed, exposing the underlying erythematosus lesions.
  • often follows use of broad spectrum antibiotics or inhaled corticosteroids
  • most common varient in HIV infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

assessment of hyperplastic candidases

A

(candidal leukoplakia)

  • chronic discrete lesions that appear as small translucent white plaques or larger opauqe lesions on tongue, palate or inner cheek
  • cannoy be wiped off easily like with pseudomembranous variant

*less common, often seen in smokers and males over 30y

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what type of oral candidiasis is condeired pre maligant

A

Hyperplastic candidiasis (candidal leukoplakia)

(biopsy recommended

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

assessment of Denture stomatitis

A

Chronic, red, edematous lesions on the denture-bearing mucosa of denture wearers.

Although usually symptomless, some result in mild soreness, burning or tingling beneath the denture.

(approx 50% of complete denture wearers experience denture stomatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Assessment of Angular cheilitis

A

Sore, erythematous fissuring at the angles of the mouth due to a mixed bacterial-fungal infection

commonly associated with denture stomatitis.

  • can be sign of vit B12, folic acid or iron deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Non pharmacologic therapy for candidiasis treatment

A

0 elimiate underlying factors for opportunisitc infection can be sufficient to help flora return to normal

  • but usually antifungal agent is required
17
Q

relationship between inhaled corticosteroids and development of oral candidiasis

A
  • assocaited with use of inhaled corticosteroids
  • can reduce the risk by usign a spacer device with metered dose inhalers, rinsing mouth and garlign with water after use, or decreasing dose if appropraite to prevent recurrent episodes of oral candidiasis
18
Q

relationship with dentures and oral candidiasis

A
  • can cause denture stomatitis or angular cheilitis
  • advise patient to:
  • remove dentures overnight and store in water
  • wear for no longer than 6 hours to allow gums to heal and reduce inflammation
  • clear dentures daily with cleaner, soak 30 min daily in proper disinfecting solution,
  • celam gums, tongue and affected mucosa area with soft tootherbursh
  • review proper fitting of dentures with oral health practiioner
  • stop smoking
19
Q

assocaition of xerostomia and oral candidiasis

A

Xerostomia = (Dry Mouth)

  • dry mouth can be caused by medication, and then lead to candidiasis
  • > suggest medication review and assessment: reduce dose or stop offending agent if possible
  • keep mouth moist by frequent sips of water, sucking on ice chips or sugar free lozenges
20
Q

what are the 3 common antifungal categories for treating oral candidiasis

A

Polyees (nystatin), azoles ((fluconazole, itraconazole, posaconazole) and echinocandins (anidulafungin, caspofungin, micafungin)

21
Q

what drug is most commonly used to tear mild oral candidiasis/ initial episodes

A

topical nystatin

  • well tolerated, does not interact with toher medications bc not largely absorbed from GI tract when administed orally

*resistance of fungi to polyenes is rare

22
Q

Why are azoles the second line therapy

A
  • mroe effective but cause mergence of azole resistant Candida strains
  • usually will prescribe fluconazole, but if resistant to that then itraconazole or posaconazole
23
Q

Why is gentian violet no longer used to treat oral candidiasis

A
  • solution was applied locally for treatment
  • the 1% concentration caused mucosal irritation, ulceration and staining -> difficult to determine therapeutic progress and decreasing adherence
  • has also been linked to carcinogenicity in animal studies so health canadia issues recall advising against do to inc risk of cancer upon exposure
24
Q

role of probiotoics for prevention of oral candidiasis

A

-some evidence by decreasing the growth of candida

25
NHP for candidiasis treamtent
insufficient evidence
26
monitoring of therapy for treatment of oral candidiasis
- most patients respond to antifunal therapy rapidly - imrpvoement to signs and symptoms can occur within 48-72 hours - adivose patients to monitor symptoms on daily basis during treatment and for up to 2 weeks after clearing of symptoms - since associated with immunocomprimised states, need to be careful to treat early bc infection could spread - - monitor patients taking broad spectrum antibiotics, undergoing chemotherapy or rradiation or taking carticosteroids orally or by inhaltion for signs and symptoms of oral candidasis
27
28
dose, adverse effects, drug interactions for oral candidiasis treatment with diflucan
* Dose * 100-200 mg daily f7-14d * preventative for recurrent infections: 100mg 3x weekly (can be daily for HIV patients( * Adverse effects * abdonimal pain, diarrhea, neusea, vomiting * drug interactions * rifampin enhaces fluconazoel metabolism (may need inc dose) * monitor prothrombin time in patiens receiving fluconazole and warfarin \*recommended treatment for mederate -\> severe - drug of choice for HIV/AIDS patients
29
dose, adverse effects, drug interactions for oral candidiasis treatment with Itraconazole (sporanox)
* Dose * capsules: 100-200 mg daily f2w * solution: 200 mg daily PO 1-2 weeks (up to 4 weeks to treat in fluconazole refractory disease * Adverse efects * abdominal pain * constipation * diarrhea * dypspepsia, heart failure, hepatotoxicity, yhpokalemia, nausea, pruritus, pulmonary edma, rash, vomiting * Drug interactions * mainly metabolized by CYP3A4, if substance share this pathway or modify its activity will influence pharmacokinetics
30
dose, adverse effects, drug interactions for oral candidiasis treatment with posaconazole (posanol)
* Dose * Oral suspension: 100mg BIG day 1, then 100 mg 1d f13d * HIV infected patients: 400 mg BIG PO dat 1, then 400 mg 1d f14d * fluconazole refractory disease: 400mg bid f3d then 400mg daily f4w * Adverse efects * diarrhea, headache, nausea * Adverse drug interactions * medabolized bia UDP glucoronidation -\> substrate for P glycoprotein * inhibitors or induced of clearance pathway can affect conc * strong inhibitor of CYP3A4 to can raise plasma levels of drugs metabolized through that pathway
31
dose, adverse effects, drug interactions for oral candidiasis treatment with Nystatin
* Dose * swish and swallow 400,000 - 600,000 units QID PO x f7-14d * infants: 100,000 units in each side of mouth QID f7-14d * adverse effects * diarrhea, GI irritation, neusea, rash urticaria, vomiting * drug interactions * no clincally significant drug interactions * GI absorption is insignificant \*recommended for initial episodes or mild disease, not as effective as azoles